Nikolay Dimitrov

Prof. Dr. Nikolay Dimitrov


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DTDimitar Tenev
Dimitar Tenev
BHBenedikt Jasper Hochbein
Benedikt Jasper Hochbein
GEGeorgi Enev
Georgi Enev
NCNikolay Cherkezov
Nikolay Cherkezov
JAJakob Adolf
Jakob Adolf
NDNikolay Dimitrov
Nikolay Dimitrov
Kienböck disease, osteonecrosis of the lunate of uncertain aetiology, presents with progressive pain, stiffness, and grip loss in dominant-hand-using adults during their most productive working years, yet its rehabilitation literature has lagged behind its surgical counterpart. This narrative review synthesises current rehabilitation evidence across conservative and post-operative pathways, mapping recommendations to disease stage and to surgical procedure. Following SANRA-aligned methods with selected PRISMA 2020 transparency elements, we appraise immobilisation and orthotic management, dart-throwing-motion-plane mobilisation, sensorimotor retraining, oedema and pain control, psychosocial screening, and procedure-specific protocols that span joint-levelling osteotomy, vascularised bone grafting (including medial femoral trochlea flap), limited intercarpal arthrodeses, proximal row carpectomy, wrist denervation, and salvage arthrodesis or arthroplasty. Patient-reported, performance-based, and occupational outcome instruments are reviewed, with explicit declaration that no Kienböck-validated MCIDs exist. We also set out an integrative reference frame that cross-walks osseous, articular, and tissue-healing axes, offered as clinical orientation rather than as a validated algorithm. The most pressing evidence gaps (Kienböck-specific functional movement screens, sustained return-to-work data, and procedure-specific rehabilitation cohorts) are translated into four registered, powered, COMET-aligned trial proposals.

15 August 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
GRGeorgi Dimitrov Raykov
Georgi Dimitrov Raykov
JAJakob Adolf
Jakob Adolf
BHBenedikt Jasper Hochbein
Benedikt Jasper Hochbein
GEGeorgi Enev
Georgi Enev
DTDimitar Tenev
Dimitar Tenev
NDNikolay Dimitrov
Nikolay Dimitrov
Biodegradable magnesium (Mg)-based implants represent a paradigm shift in orthopedic biomaterials, offering temporary mechanical support, inherent osteogenic bioactivity, and elimination of hardware removal surgery. These properties are particularly attractive for sports orthopedic applications, including anterior cruciate ligament (ACL) reconstruction, rotator cuff repair, meniscal fixation, and osteochondral fragment refixation, where young, active patients demand rapid return to function and where permanent metallic hardware poses long-term risks of stress shielding, imaging artifact, and reoperation. Despite extensive preclinical evidence demonstrating that Mg-based interference screws promote fibrocartilaginous enthesis regeneration, attenuate peri-tunnel bone loss, and achieve biomechanical fixation comparable to titanium, no human clinical trial has yet evaluated Mg fixation devices for soft-tissue reconstruction in sports medicine. Meanwhile, clinical fracture fixation data from over 468 patients across multiple trials and a meta-analysis confirm complication rates equivalent to those of titanium. This narrative review synthesizes the current evidence on Mg alloy design, surface engineering strategies, preclinical sports medicine applications, clinical translation in fracture fixation, imaging compatibility, and the remaining barriers to clinical adoption in sports orthopedic surgery. By mapping the translational gap between promising animal data and the absence of clinical sports medicine trials, this review aims to guide future research priorities and accelerate the pathway toward clinical application of Mg-based devices in sports orthopedics.

1 September 2026 in Medicines
Verified
Journal Article
Open access
PDF file
DTDimitar Tenev
Dimitar Tenev
BHBenedikt Jasper Hochbein
Benedikt Jasper Hochbein
GEGeorgi Enev
Georgi Enev
GRGeorgi Dimitrov Raykov
Georgi Dimitrov Raykov
NCNikolay Cherkezov
Nikolay Cherkezov
NDNikolay Dimitrov
Nikolay Dimitrov
Background/Objectives: Kienböck disease (idiopathic avascular necrosis of the lunate) is treated almost exclusively surgically; its pharmacological evidence base comprises fewer than five primary publications and ~20 patient-level observations. Femoral-head, jaw, and knee osteonecrosis have decades of evidence, including randomised trials. We ask whether extra-carpal evidence can be translated to Kienböck disease and the wider Carpal Avascular Necrosis Family (lunate, scaphoid/Preiser, capitate, hamate, triquetrum). Methods: We conducted a narrative review reported per SANRA, searching PubMed, CrossRef, Google Scholar and three specialty registries from inception to 2026 across eleven drug classes and eleven skeletal sites. All references were independently verified against primary sources (PubMed/CrossRef). No Kienböck-specific randomised or controlled data exist; all conclusions therefore rest on indirect, extra-carpal evidence. Results: Three pathways (subchondral insufficiency fracture, microvascular ischaemia, hypercoagulability) predict drug-class plausibility differently by site. Iloprost is the candidate most consistently aligned across the translation axes, though no direct lunate data exist; teriparatide provides the only randomised evidence suggesting reversal of established osteonecrosis at any site (medication-related osteonecrosis of the jaw). The lunate sits within a coherent carpal AVN family sharing end-arterial supply, Lichtman-grade trajectories, and a near-identical evidence vacuum. Conclusions: A Four-Axis Translation Framework (mechanistic alignment, anatomic concordance, Lichtman-stage applicability, lunate-specific risk–benefit geometry) is proposed to evaluate which extra-carpal evidence is admissible at the lunate; with the carpal AVN family construct, these are the review’s two novel contributions.

16 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DTDimitar Tenev
Dimitar Tenev
NCNikolay Cherkezov
Nikolay Cherkezov
GEGeorgi Enev
Georgi Enev
GRGeorgi Dimitrov Raykov
Georgi Dimitrov Raykov
NDNikolay Dimitrov
Nikolay Dimitrov
Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and fracture risk. Estrogen deficiency is its principal cause in postmenopausal women, sex steroid deficiency is a common cause in men, and several fracture-preventing drugs act on hormonal pathways, although the most widely prescribed agents, the bisphosphonates and denosumab, do not. This narrative review summarizes the randomized trial evidence for estrogen, selective estrogen receptor modulators, the tissue-selective estrogen complex, tibolone, progestogens, parathyroid hormone receptor agonists, and androgens, and for the iatrogenic hypogonadal states produced by androgen deprivation therapy, aromatase inhibitors, gonadotropin-releasing hormone agonists, and glucocorticoids. PubMed, Embase, and the Cochrane Library were searched to September 2026, with priority given to randomized trials with fracture endpoints. Estrogen reduces vertebral and hip fracture in women recruited without regard to bone mineral density, and the benefit ends when treatment ends. Parathyroid hormone receptor agonists produce the largest early reduction in vertebral fracture of any hormonal agent, and the gain is lost unless an antiresorptive drug follows. Testosterone raises bone mineral density in older men but did not reduce fracture in the one adequately powered randomized trial, in which fracture incidence was higher on treatment than on placebo. Hormonal agents are therefore selected for their extraskeletal profile or to correct a hormonal deficit, alongside rather than in place of bisphosphonates, denosumab, and romosozumab. Implications for fracture liaison, perioperative planning, and implant fixation are discussed, and the open questions are stated as specific comparisons.

10 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DTDimitar Tenev
Dimitar Tenev
NCNikolay Cherkezov
Nikolay Cherkezov
GEGeorgi Enev
Georgi Enev
GRGeorgi Dimitrov Raykov
Georgi Dimitrov Raykov
NDNikolay Dimitrov
Nikolay Dimitrov
Kienböck disease is osteonecrosis of the lunate, and it is usually diagnosed late. In one series, symptoms had lasted a mean of 33 months before evaluation, and almost half of the wrists were Lichtman stage IIIB or worse at the first visit, when the options that preserve the lunate are already limited. This narrative review, written with the Scale for the Assessment of Narrative Review Articles (SANRA) as a checklist, summarises evidence published mainly between 2015 and 2026 with two emphases: the timing of diagnosis and the whole range of treatment. Registry data now give a measured incidence. Negative ulnar variance and capitate morphology carry quantified risk. Magnetic resonance imaging is needed when radiographs are normal, computed tomography upstages a third of radiographically staged wrists, and arthroscopy changes the plan in a substantial minority. Treatment runs from immobilisation, which can be definitive in children and low-demand adults, through joint levelling, capitate shortening, core decompression and revascularisation to limited fusion, proximal row carpectomy, implants and salvage. Comparative studies exist, including five small randomised trials, but their size, design and heterogeneity do not establish a consistently superior strategy at any stage. We relate each option to the stage at diagnosis and specify the studies still needed.

10 October 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
VAVladislav Andonov
Vladislav Andonov
VVVensan Velchov
Vensan Velchov
YNYasen IVo Nikolov
Yasen IVo Nikolov
NCNikolay Cherkezov
Nikolay Cherkezov
DTDimitar Tenev
Dimitar Tenev
NDNikolay Dimitrov
Nikolay Dimitrov
Background: Total hip arthroplasty (THA) and the diagnosis of periprosthetic joint infection (PJI) have each acquired a technology that measures with high precision: intraoperative navigation, which reports component position to within a few degrees, and molecular methods, which identify the infecting organism and the host response at genomic resolution. Objective: To establish whether the measured accuracy has been shown to reach the patient as a clinical outcome. Methods: This is a narrative review, reported according to SANRA. MEDLINE, Scopus, and Web of Science databases were searched from inception to 31 August 2026. English-language studies in humans were eligible if they reported positional or diagnostic accuracy, a patient-level clinical or economic outcome after THA or after treatment of PJI or osteomyelitis, or a factor modifying the relation between the two. Animal, in vitro, and cadaveric studies, conference abstracts, and reports without extractable data were excluded. Forty studies were included. No pooled estimate was calculated, and no new statistical analysis was performed. Results: Navigation reduced positional outliers consistently, but in two matched claims-based cohorts of patients with morbid obesity (4499 and 5835 patients), it was not associated with lower rates of PJI, dislocation, periprosthetic fracture, mechanical loosening, or revision within two years. Candidate immunogenetic variants in osteomyelitis have never been tested against a treatment decision. Metagenomic sequencing was no more accurate than culture (sensitivity 63.2% versus 68.4%; specificity 80.0% versus 95.0%) except after antibiotic exposure. Reported infection rates and test accuracy both change with the case definition applied. Conclusions: In both settings, the limiting factor is the design of the studies linking measurement to outcome rather than the precision of the measurement.